Evidence map›Paper›PMID 21057550›Full record

ArticleBone marrow transplantation2011

Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma.

B Čunderlíková, V Vasovič, F Sieber, T Furre, E Borgen, J M Nesland, Q Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

B ČunderlíkováDepartment of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
V Vasovič
F Sieber
T Furre
E Borgen
J M Nesland
Q Peng

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not effective in eradicating 4T1 cells when the tumor cells were mixed with murine marrow cells in vitro. However, the number of pulmonary metastases was reduced, and the survival of experimental animals was prolonged substantially when they were subjected to TBI followed by transplantation of syngeneic BM containing metastasized 4T1 cells that had been treated ex vivo by HAL-PDT. Despite the failure of in vitro experiments, HAL-based photodynamic purging could be a useful modality for treating animals bearing an experimental breast carcinoma.

Indexed as

Aminolevulinic AcidAnimalsBone MarrowBone Marrow PurgingCell Line, TumorFemaleHematopoietic Stem Cell TransplantationLung NeoplasmsMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CPhotochemotherapyPhotosensitizing AgentsProtoporphyrinsTumor Cells, Cultured5-aminolevulinic acid hexyl esterAminolevulinic AcidPhotosensitizing Agentsprotoporphyrin IXProtoporphyrins

Identifiers

PMID21057550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.